Candel Therapeutics, Inc.
CADL
$4.95
-$0.10-1.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.55% | 12.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.22% | 18.16% | |||
| Operating Income | -19.22% | -18.16% | |||
| Income Before Tax | -161.74% | -134.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -161.74% | -134.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -161.74% | -134.97% | |||
| EBIT | -19.22% | -18.16% | |||
| EBITDA | -19.75% | -18.99% | |||
| EPS Basic | -161.71% | -120.52% | |||
| Normalized Basic EPS | -161.65% | -120.45% | |||
| EPS Diluted | -161.71% | -120.52% | |||
| Normalized Diluted EPS | -161.65% | -120.45% | |||
| Average Basic Shares Outstanding | 0.01% | 6.61% | |||
| Average Diluted Shares Outstanding | 0.01% | 6.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||